• SSY Group's unaudited shareholder profit rose 15.5% to HK$ 460 million for the nine months ended September 30, 2026.
• Revenue increased 13.5% to HK$ 3.52 billion, driven by recovery in intravenous infusion solutions and bulk pharmaceuticals.
• Gross profit grew 11.4% to HK$ 1.44 billion.
• Gross margin narrowed 0.7 percentage point to 41%.
• Oral preparations revenue fell 34.7% to HK$ 268 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382757), on October 26, 2026, and is solely responsible for the information contained therein.